DOI: https://doi.org/10.18370/2309-4117.2018.43.62-67

Predictors of reproductive health disorders

Т. Ф. Татарчук

Abstract


«Bell» indicating a change in reproductive health is menstrual cycle disorders. 10–28% of the total number of endocrine gynecological diseases is menstrual cycle disorders, its clinical manifestations are absence of menstruation or rare or poor menstruation, as well as subclinical manifestations in the form of infertility and miscarriage. If there is irregular menstrual cycle, it is necessary to consider the diagnosis of polycystic ovary syndrome.

In the International evidence-based guideline for the assessment and management of polycystic ovary syndrome from 2018, a new treatment site appears phytotherapy, which has a hormone-correcting action. Its use is due to the fact that the polycystic ovaries syndrome is a life-long condition and need of long-term correction. For these purpose phytohormones without estrogenpositive activity flavonoids are used. Tazalok™ is one of such drugs. It blocks estrogen (androgen) receptors in the mammary glands, ovaries and uterus, normalizes estrogen-progestin balance (restores the hormonal balance).

It has been established that correlation between the hormones of the adipose tissue and the indices of the functional activity of the hypothalamic-adrenal and hypothalamic-oocyte systems in patients with polycystic ovaries syndrome is lost. In this regard, a study was conducted to investigate the possibility of using the multicomponent herbal preparation Tazalok™ in the complex treatment of polycystic ovary syndrome in women with obesity and normal level of ovarian androgens. As a result, it was found that the inclusion in the treatment scheme of this drug gives possible normalize the function of adipose tissue and improve its relationship with the pituitary-adrenal and pituitar-ovarian systems, normalize the menstrual cycle.

If it is necessary to restore the menstrual cycle the combined oral contraceptives should also be prescribed. They restore the menstrual cycle, which is the prevention of endometrial cancer, eliminating hypomenorrhea and hyperpolymenorrhea. The higher dose of estrogen in combined oral contraceptives is better kept the cycle, lead to less bleeding, but there is higher the thrombotic risk.


Keywords


menstrual cycle disorders; polycystic ovary syndrome; phytotherapy; combined oral contraceptives; Tazalok

References


Mallinson, R.J., De Souza, M.J. “Current perspectives on the etiology and manifestation of the «silent» component of the Female Athlete Triad.” Int J Womens Health 6 (2014): 451–67. DOI: 10.2147/IJWH.S38603

Ibanez, L., Oberfield, S.E., Witchel, S., et al. “International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence.” Horm Res Paediatr 88 (2017): 371–95. DOI: 10.1159/000479371

Un Ju Jung, Myung-Sook Choi. “Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver DiseaseInt.” Int J Mol Sci 15.4 (2014): 6184–223. DOI: 10.3390/ijms15046184

Reznikov, O.G., Tarasenko, L.V., Sinitsin, P.V., et al. “Anti-estrogenic activity of phytodrug Tazalokтм: results of experimental study.” Reproductive endocrinology 1.3 (2012): 90–2.

Rice, S., Whitehead, S.A. “Phytoestrogens and breast cancer – promoters or protectors?” Endocr Relat Cancer 13.4 (2006): 995–1015.

Sarkar, F.H., Adsule, S., Padhye, S., et al. “The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy.” Mini Rev Med Chem 6 (2006): 401–7.

Tatarchuk, T.F., Ganzhii, I.Y., Pedachenko, N.Y., Kapshuk, I.M. “Modern features of non-hormonal treatment of polycystic ovary syndrome in obese women.” Reproductive endocrinology 5.13 (2013): 14–21.

Fauser, B.C.J.M., et al. “Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.” Fertil Steril 97.1 (2012): 28–38.e25. DOI: 10.1016/j. fertnstert.2011.09.024

Maybin, J.A., Critchley, H.O. “Menstrual physiology: implications for endometrial pathology and beyond.” Hum Reprod Update 21.6 (2015): 748–61.


GOST Style Citations


1.       Mallinson, R.J., De Souza, M.J. “Current perspectives on the etiology and manifestation of the «silent» component of the Female Athlete Triad.” Int J Womens Health 6 (2014): 451–67. DOI: 10.2147/IJWH.S38603

2.       Ibanez, L., Oberfield, S.E., Witchel, S., et al. “International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence.” Horm Res Paediatr 88 (2017): 371–95. DOI: 10.1159/000479371

3.       Un Ju Jung, Myung-Sook Choi. “Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver DiseaseInt.” Int J Mol Sci 15.4 (2014): 6184–223. DOI: 10.3390/ijms15046184

4.       Рєзніков, О.Г. Антиестрогенна активність фітопрепарату Тазалоктм: результати експериментального дослідження / О.Г. Рєзніков, Л.В. Тарасенко, П.В. Сініцин та ін. // Репродуктивна ендокринологія. – 2012. – №1 (3). – С. 90–92.

5.       Rice, S., Whitehead, S.A. “Phytoestrogens and breast cancer – promoters or protectors?” Endocr Relat Cancer 13.4 (2006): 995–1015.

6.       Sarkar, F.H., Adsule, S., Padhye, S., et al. “The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy.” Mini Rev Med Chem 6 (2006): 401–7.

7.       Татарчук, Т.Ф. Сучасні можливості негормонального лікування синдрому полікістозних яєчників у жінок із ожирінням / Т.Ф. Татарчук, І.Ю. Ганжий, Н.Ю. Педаченко, І.М. Капшук // Репродуктивна ендокринологія. – 2013. – №5 (13). – С. 14–21.

8.       Fauser, B.C.J.M., et al. “Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.” Fertil Steril 97.1 (2012): 28–38.e25. DOI: 10.1016/j. fertnstert.2011.09.024

9.       Maybin, J.A., Critchley, H.O. “Menstrual physiology: implications for endometrial pathology and beyond.” Hum Reprod Update 21.6 (2015): 748–61.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)